文章摘要

文章信息/Info

Title:: -

作者:: 王江; 田颖; 祝善俊; 第三军医大学新桥医院全军心血管内科中心，重庆 400037

Author(s):: -

关键词:: 醛固酮; 螺内酯; 心力衰竭

Keywords:: -

分类号:: R541.61

DOI:: -

文献标识码:: A

摘要:: 近年来发现心脏是醛固酮作用的靶器官，血浆醛固酮水平与心力衰竭（HF）患者病死率、心室壁厚度和左心室重量呈明显正相关，越来越多的临床资料提示血浆醛固酮水平升高可作为心血管病变的危险因子，而抗醛固酮治疗能降低HF患者死亡率。本文综述了醛固酮在心衰中的病理生理作用以及抗醛固酮治疗的最新进展。

Abstract:: -

参考文献/References

［1］臧益民，臧伟进，王晓明. 心力衰竭的病理生理机制及治疗概述［J］. 心脏杂志,2002,14(5):417-419.

［2］ Cicoira M, Zanolla L, Franceschini L, et al. Relation of aldosterone "escape" despite angiotensinconverting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy［J］. Am J Cardiol, 2002, 89（4）: 403-407.

［3］ Mihailidou AS, Bundgaard H, Mardini M, et al. Hyperaldosteronemia in rabbits inhibits the cardiac sarcolemmal Na+-K+ pump［J］. Circ Res, 2000, 86（1）: 37-42.

［4］ Rocha R, Williams GH. Rationale for the use of aldosterone antagonists in congestive heart failure［J］. Drugs, 2002, 62: 723-731.

［5］ Fiebeler A, Schmidt F, Muller DN, et al. Mineralocorticoid receptor affects AP1 and nuclear factorkappab activation in angiotensin IIinduced cardiac injury［J］. Hypertension, 2001, 37（2 part 2）: 787-793.

［6］ Rocha R, Rudolph AE,Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart［J］. Am J Physiol Heart Circ Physiol, 2002, 283(5):H1802-H1810.

［7］ Weber KT, Sun Y, Wodi LA, et al. Toward a broader understanding of aldosterone in congestive heart failure［J］. J Renin Angiotensin Aldosterone Syst, 2003, 4(3): 155-163.

［8］ Rajagopalan S, Duquaine D, King S, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis［J］. Circulation, 2002, 105(18): 2212-2216.

［9］ Tsutamoto T, Wada A, Maeda K, et al. Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure［J］. J Cardiovasc Pharmacol, 2003, 41（Suppl 1）: S19-S22.

［10］Delyani JA, Rocha R, Cook CS, et al. Eplerenone : A selective aldosterone receptor antagonist (SARA)［J］. Cardiovasc Drug Rev, 2001, 19(3):185-200.

［11］Salam AM. Selective aldosterone blockade with eplerenone in patients with congestive heart failure［J］. Expert Opin Investig Drugs, 2003, 12: 1423-1427.

［12］Thohan V, TorreAmione G, Koerner MM. Aldosterone antagonism and congestive heart failure: a new look at an old therapy［J］. Curr Opin Cardiol, 2004, 19: 301-308.

［13］Schafer A, Fraccarollo D, Hildemann S, et al. Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition［J］. Thromb Haemost, 2003, 89: 1024-1030.

［14］Bureik M, Hubel K, Dragan CA, et al. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11betahydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension［J］. Mol Cell Endocrinol, 2004, 217: 249-254.

［15］Sica DA, Gehr TW, Yancy C. Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism［J］. Congest Heart Fail, 2003, 9: 224-229.

［16］Ramires FJ, Mansur A, Coelho O, et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy［J］. Am J Cardiol, 2000, 85(10): 1207-1211.

我们的网站为什么显示成这样？

Aldo与充血性心力衰竭(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics